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Abstract
Our understanding of the expanded genetic alphabet has been growing
rapidly over the last two decades, and many of these developments came
more than 80 years after the original discovery of a modified guanine in
tuberculosis DNA. These new understandings, leading to the field of
epigenetics, have led to exciting new fundamental and applied knowledge
and to the development of novel classes of drugs exploiting this new
biology. The number of methyl modifications to RNA is about seven times
greater than those found on DNA, and our ability to interrogate these
enigmatic nucleobases has lagged significantly until recent years as an
explosion in technologies and understanding has revealed the roles and
regulation of RNA methylation in several fundamental and
disease-associated biological processes. Here, we outline how the
technology has evolved and which strategies are commonly used in the
modern epitranscriptomics revolution and give a foundation in the
understanding and application of the rich variety of these methods to novel
biological questions.
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Introduction
Beyond the basic genetic letters of A, G, C, and U, chemically 
modified nucleotides can be found in the RNA of all eukaryo-
tes. Though originally characterised in the 1970s1–4, methyl 
modifications to messenger RNA (mRNA) have been thrust 
back into the spotlight of late because of the availability of new 
technology and understanding which have revealed links with 
fundamental genetic processes and disease. In DNA, the inten-
sive study of modified nucleotides during the last 20 years of the 
epigenetics revolution has led to the understanding of the role 
of DNA modifications in swathes of developmental decisions 
and disease. The epigenetics revolution has resulted in novel 
drugs, including DNA methylation inhibitors, bromodomain 
inhibitors, and histone acetyl transferase inhibitors5.
Whereas only a handful of methylated nucleotides are found 
in DNA, dozens are found in RNA, including the 72 methyl- 
group modifications listed on the MODOMICS database6. 
Most of these modifications (Table 1) are found on the nucle-
oside base rather than the sugar-phosphate backbone (Figure 1) 
and only a few of these are found on mRNA, the protein-coding 
RNA species.
Table 1. Methyl modifications to RNA.
Name Short name Modified edge Found on 
mRNA
Typical location
2’-O-methyladenosine Am Sugar Yes Cap1, Cap2
2’-O-methylcytidine Cm Sugar Yes Cap1, Cap2
2’-O-methylguanosine Gm Sugar Yes Cap1, Cap2
2’-O-methyluridine Um Sugar Yes Cap1, Cap2
N6,2’-O-dimethyladenosine m6Am Sugar and Watson–Crick Yes Cap1
1-methyladenosine m1A Watson–Crick Yes Internal
1-methylguanosine m1G Watson–Crick Yes Internal
5-methylcytidine m5C Watson–Crick Yes Internal
N6-methyladenosine m6A Watson–Crick Yes Internal
7-methylguanosine m7G Watson–Crick Yes Cap structure (Cap0, Cap1, Cap2)
7-methylguanosine cap (cap 0) m7Gpp(pN) Watson–Crick Yes Cap structure (Cap0, Cap1, Cap2)
N2,N2,7-trimethylguanosine m2,2,7G Watson–Crick No Cap structure (snRNA)
N2,N2,7-trimethylguanosine cap (cap TMG) m2,2,7Gpp(pN) Watson–Crick No Cap structure (snRNA)
N2,N2-dimethylguanosine m2,2G Watson–Crick No Cap structure (snRNA)
N2,7-dimethylguanosine m2,7G Watson–Crick No Cap structure (snRNA)
N2,7-dimethylguanosine cap (cap DMG) m2,7Gpp(pN) Watson–Crick No Cap structure (snRNA)
N4-acetyl-2’-O-methylcytidine ac4Cm Sugar and Watson–Crick No
5-carboxymethylaminomethyl-2’-O-
methyluridine
cmnm5Um Sugar and Watson–Crick No
5-formyl-2’-O-methylcytidine f5Cm Sugar and Watson–Crick No
1,2’-O-dimethylguanosine m1Gm Sugar and Watson–Crick No
1,2’-O-dimethylinosine m1Im Sugar and Watson–Crick No
N2,N2,2’-O-trimethylguanosine m2,2Gm Sugar and Watson–Crick No
N2,7,2’-O-trimethylguanosine m2,7Gm Sugar and Watson–Crick No
N2,2’-O-dimethylguanosine m2Gm Sugar and Watson–Crick No
3,2’-O-dimethyluridine m3Um Sugar and Watson–Crick No
N4,N4,2’-O-trimethylcytidine m4,4Cm Sugar and Watson–Crick No
N4,2’-O-dimethylcytidine m4Cm Sugar and Watson–Crick No
5,2’-O-dimethylcytidine m5Cm Sugar and Watson–Crick No
5,2’-O-dimethyluridine m5Um Sugar and Watson–Crick No
N6,N6,2’-O-trimethyladenosine m6,6Am Sugar and Watson–Crick No
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Name Short name Modified edge Found on 
mRNA
Typical location
isowyosine imG2 Watson–Crick No
5-carboxymethylaminomethyl-2-thiouridine cmnm5s2U Watson–Crick No
5-carboxymethylaminomethyl-2-
selenouridine
cmnm5se2U Watson–Crick No
5-carboxymethylaminomethyluridine cmnm5U Watson–Crick No
5-cyanomethyluridine cnm5U Watson–Crick No
2’-O-methylinosine Im Sugar No
1-methyl-3-(3-amino-3-carboxypropyl)pseu
douridine
m1acp3Y Watson–Crick No
1-methylinosine m1I Watson–Crick No
1-methylpseudouridine m1Y Watson–Crick No
2,8-dimethyladenosine m2,8A Watson–Crick No
2-methyladenosine m2A Watson–Crick No
N2-methylguanosine m2G Watson–Crick No
3-methylcytidine m3C Watson–Crick No
3-methyluridine m3U Watson–Crick No
3-methylpseudouridine m3Y Watson–Crick No
N4,N4-dimethylcytidine m4,4C Watson–Crick No
N4-methylcytidine m4C Watson–Crick No
5-methyldihydrouridine m5D Watson–Crick No
5-methyl-2-thiouridine m5s2U Watson–Crick No
5-methyluridine m5U Watson–Crick No
N6,N6-dimethyladenosine m6,6A Watson–Crick No
N6-methyl-N6-threonylcarbamoyladenosine m6t6A Watson–Crick No
8-methyladenosine m8A Watson–Crick No
5-methoxycarbonylmethyl-2’-O-methyluridine mcm5Um Sugar and Watson–Crick No
methylwyosine mimG Watson–Crick No
5-methylaminomethyl-2-thiouridine mnm5s2U Watson–Crick No
5-methylaminomethyl-2-selenouridine mnm5se2U Watson–Crick No
5-methylaminomethyluridine mnm5U Watson–Crick No
2-methylthio-N6-methyladenosine ms2m6A Watson–Crick No
5-carbamoylmethyluridine ncm5U Watson–Crick No
5-carbamoylmethyl-2’-O-methyluridine ncm5Um Sugar and Watson–Crick No
5-aminomethyl-2-thiouridine nm5s2U Watson–Crick No
5-aminomethyl-2-selenouridine nm5se2U Watson–Crick No
5-aminomethyluridine nm5U Watson–Crick No
2-thio-2’-O-methyluridine s2Um Watson–Crick No
5-taurinomethyl-2-thiouridine tm5s2U Watson–Crick No
5-taurinomethyluridine tm5U Watson–Crick No
2’-O-methylpseudouridine Ym Sugar No
Initial list taken from MODOMICS6, redundant entries removed (for example, m7G and m7Gppp considered the same for the purpose of this review). Entries are 
annotated with simple information including: The modified edge of the nucleotide (i.e. whether the methyl group is found on the base itself or the sugar); the 
species of RNA the modification is normally found on; and the typical position of the modified nucleotide along an mRNA transcript where relevant..
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Figure 1. Anatomies of mRNA, nucleotides, and modified nucleotides. Simple diagram of the epitranscriptomic marks found on messenger 
RNA, given in the context of the 5′ cap and cap-adjacent structures, typical internal modifications, and the poly(A) tail (A). The relevant 
anatomy of a nucleotide (in this case, adenosine) for the purposes of detection of methylations to the base or ribose sugar is shown in (B). A 
diagrammatic explanation of the naming convention which describes the base and methylated position to arrive at a simplistic name for the 
methylated form “m6A” is shown in (C).
Methyl modifications to RNA form a system of post-transcrip-
tional control mechanisms allowing the fine tuning of gene 
expression by modifying how the RNA interacts with other 
components of the cell. Whilst many RNA species are depend-
ent on their methyl groups for their structure and function, 
the methylation of mRNA and long non-coding RNA appears 
to possess a level of dynamism that allows the fine tuning of 
protein-coding genes and cellular processes. Modifications to 
ribosomal RNA, transfer RNA, and other non-coding RNAs 
remain active and vibrant fields of research in the area7.
The role of the 5′ Cap and poly(A) tail is centred on the 
metabolism of the mRNA molecule rather than the encoded 
information. These structures are not coded for in the DNA but 
are found on the vast majority of mRNA molecules and have 
well-established roles in message stabilisation, nuclear export, 
and translation initiation8; as a result, these structures are not 
normally considered part of the “epitranscriptome”. Owing to the 
location of the modifications (Figure 1) and lack of an antibody 
and chemical or enzymatic method to readily allow detection, the 
cap-adjacent Cap1 and Cap2 ribose methylations are less well 
understood, although they are involved in the innate immune 
system and the discerning of self from non-self messages9.
Previous works had linked internal N6-methylation of 
adenosine to fundamental biological processes and develop-
mental decisions10, but in 2011, evidence that the fat mass and 
obesity-associated protein, FTO, was able to remove the N6 
methylation from mRNA was published, linking the modifica-
tion to those diseases associated with FTO11–14 and reigniting the 
interest in mRNA methylation, its detection, and its biologi-
cal impacts. More recent works have linked the modification 
to various processes, from the fundamental such as alternative 
splicing15,16 to diseases, including cancer17.
Other common epitranscriptomic marks not covered here 
include the editing of adenosine-to-inosine18 and pseudouri-
dylation19. These modifications do not involve methylation but 
can affect the metabolism of the RNA without modifying the 
coding sequence.
These developments led to the field of the “epitranscriptome”, 
a field of molecular biology that attempts to characterise the 
causes and effects of modifications to the nucleotides of mRNA 
that affect not the coding sequence but rather the expression 
characteristics of the transcript. Understanding these modifi-
cations will allow a new level of fine tuning of gene expression 
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and has great potential in fundamental biology, medicine, 
biotechnology, and crop production20.
It is the availability of technology that has driven these new 
fundamental understandings as well as the gap in knowledge of 
the base modifications and ribose modifications. A bisulphite 
approach used for DNA m5C analysis has also been adapted 
for RNA21. Similarly, methylations or modifications to the 
base-pairing “Watson–Crick edge” (Figure 1) of the nucleotide 
may sometimes affect the cDNA molecule produced, allowing 
identification through bioinformatics. Modifications on the 
“sugar edge” of the RNA molecule do not appear to affect 
the enzymes involved in reverse transcription under normal 
conditions. As a result of these limitations, a whole-transcrip-
tome analysis of the 2’-O-ribose methylations on mRNA has not 
yet been published.
This work focusses on the strategies used to detect and 
analyse RNA methylation with a particular focus on those 
modifications found in mRNA. These methods are used to 
identify methylation targets and locations on the transcript and, 
alongside other methods, to unravel the downstream effects 
on the mRNA life cycle.
From “a fifth nucleotide” to the epitranscriptomics 
revolution
The first modifications to nucleotides were reported in 192522, 
the first of the “fifth nucleotides” was 5-methyl-cytosine, and 
early work focussed primarily on the detection and characterisa-
tion of the modifications themselves23. It would be several decades 
before the technological expertise and availability would allow 
the location and their biological consequences to be understood, 
leading to the epigenetics revolution of the 2000s24.
The methods used to identify modified nucleotides can some-
times be applied to both DNA and RNA, although owing to the 
differences in the modified bases, the biochemical structure 
of RNA, and the fundamental properties of sequencing 
technologies, the techniques used to study RNA methylation have 
diverged significantly.
Curiously, there have been several reports of a “fifth nucle-
otide”, These are usually reporting on different modified nucle-
otides and has become a hyperbolic term for newly discovered 
nucleotides in DNA or RNA. As a result, the “fifth nucleotide” 
can often be ignored – but most likely refers to 5mC in DNA, 
and m6A in mRNA.
Common considerations
Detection of the type of methylation found in RNA is preceded 
by a number of well-established methods for the purification of 
RNA25. A typical workflow for the purification of mRNA will 
include the initial isolation of total RNA, followed by the 
purification of mRNA by their poly(A) tails using oligoDT or 
by depleting ribosomal RNA through a number of available 
strategies25. Since mRNA constitutes only 1 to 5% of the total 
RNA and the other RNA species can be heavily methylated, 
several rounds of purification are often required for reliable, 
consistent data from mRNA.
Depending on the downstream protocol, as little as 50 ng of 
mRNA, as measured by spectrophotometry, may be required. 
The quality of the RNA is paramount to generating high- 
quality data and typically is measured by using agarose gel 
electrophoresis or microfluidic analysis such as the Agilent 
bioanalyzer (Agilent, Santa Clara, CA, USA). The subsequent 
characterisation and analysis of the RNA depend on the type of 
modification (Figure 1), the abundance of the modification, and 
any pre-existing knowledge of its sequence context (Table 2).
Radioisotope incorporation assays
The earliest works on RNA methylation were carried out by 
incorporating radioactive isotopes into the RNA. Labelling the 
methyl donor, s-adenosyl-methionine, with tritium (3H) enables 
the measurement of methyltransferase activity by scintillation26 
as the radioactive methyl group is added onto the nucle-
oside. Combining this simple assay with various biochemical 
tools enabled early identification of methyltransferase activity, 
the initial identification of the m6A writer complex27, and the 
characterisation of the properties of various enzymes. However, 
the use of the method is limited where sequence context is 
desired or in the assaying of ex vivo RNA.
Table 2. Strategies for the detection of RNA methylation.
Method type Input quantity Resolution Stoichiometry 
information
Sequence 
data
Types of modification 
detected
Radioisotope incorporation Medium Low Medium Nil All
Thin-layer chromatography Low Low High Low All
Mass spectrometry High Medium Medium Low All
Differential enzyme/chemical–RNA 
interactions
High High Low Maintained Ribose
Bisulphite RNA sequencing High High Low Maintained m5C
Antibody-based sequencing High High Low Maintained Base methylations
Big data None Low Very low Maintained All
A brief summary of the commonly used methods for detecting modifications to nucleotides in RNA.
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Thin-layer chromatography
A “fifth ribonucleotide” in yeast RNA was first reported in 
1957 when Davis and Allen28 published their paper chroma-
tography analysis of previously discarded RNA preparation 
fractions. These paper chromatography assays evolved over time 
into two-dimensional thin-layer chromatography (2D-TLC) 
capable of identifying most of the modified nucleotides present 
in RNA29. By separating RNA in two dimensions, the nucle-
otides disperse across the typically cellulose substrate according 
to their charge and hydrophobicity, two attributes affected by 
methylation. The pattern then can be imaged with ultraviolet 
light or by pre-labelling the RNA with radioisotopes. The numer-
ous advances in isolation of RNA, mRNA, and individual 
mRNA have enabled the adaptation of this method to assay for 
both internal m6A10 and cap-adjacent modifications Nm and 
m6Am30, resulting in a sensitive, quantitative and reproducible 
strategy.
The modern methods require that the RNA be prepared in such 
a way that the nucleotide of interest is exposed at the 5′ end of 
the transcript. For example, digesting mRNA with RNAse T1 
which, cutting after every guanine, exposes any nucleotide 
following a guanine, thereby exposing adenosines found within 
the canonical m6A motif to 5’ end labelling. The 5′-most 
nucleotide then can be labelled with a radioactive phosphate 
group from γ-32P-ATP. These then can be separated on 2D-TLC 
and the resultant spots can be imaged and quantified with auto-
radiography. Enzymatic decapping and dephosphorylating of 
the 5′ end of intact mRNA reveal the nucleotide immedi-
ately adjacent to the 5′ cap, enabling the assaying of the cap1 
structure30.
Where sequence information is already known, site-specific 
cleavage and radioactive labelling followed by ligation-assisted 
extraction and thin-layer chromatography (SCARLET)31 can be 
used to assay the stoichiometry (ratio of modified to unmodi-
fied nucleotide) of the methylation at a known site. Here, a 2’-
ribose methylated single-stranded DNA (ssDNA) probe comple-
mentary to the target site is used to direct RNAse-H–mediated 
cleavage, exposing the nucleotide for subsequent 2D-TLC 
analysis.
2D-TLC has been used to identify and characterise the location 
of various methylated nucleotides and was used in the first 
mapping of the locations of m6A in bovine prolactin mRNA32. 
These works localised the m6A modification to the 3′ end of 
eukaryotic mRNA10,32,33, reported on the phenotypic abnormali-
ties resulting from knockouts in a reverse genetics approach10,33, 
as well as pointing towards their roles in developmental 
decisions34,35.
Owing to the modest quantities of mRNA required and the pres-
ervation of stoichiometry information, recent studies continue 
to use 2D-TLC in combination with other methods to allow 
a detailed analysis of the methylation states of internal and 
cap-adjacent nucleotides. However, 2D-TLC–based methods 
are often avoided because of their use of radioisotope and 
sensitivity to degradation, they also require a method of revealing 
the modified nucleotide and thus will miss modifications 
outside of a known context or sequence, or where it is not 
possible to reliably expose only the nucleotide of interest, such 
as the cap2 nucleotide. 2D-TLC provides excellent stoichio-
metric information but provides only a general transcriptome- 
wide view of the methylation status and yields little insight into 
the sequence specificity.
Mass spectrometry
In combination with separation based on biophysical proper-
ties, mass spectrometry (MS) can identify nucleotides by the 
mass-to-charge ratio in comparison with known standards. 
In many ways, MS identification is similar in principle to the 
chromatography-based methods but without the need for radio-
isotope or specific exposure of the nucleotide of interest for 
labelling. The method can detect methylation on the sugar and 
Watson–Crick edges of the nucleotide. MS also enables the 
profiling of methylations found on a variety of RNA fragments, 
including the cap2 structures that are typically inaccessible in 
2D-TLC. Enhanced by the available sequencing information, 
MS has been used to map the modifications to transfer RNA 
(tRNA)36.
Using MS in the analysis of mRNA has been performed to aid in 
the measurement of Cap1 and Cap2 structures. However, a major 
drawback of MS-based methods is the extremely large quanti-
ties of RNA required and the need for pre-existing sequencing 
information for the most informative results to be generated.
Bisulphite sequencing
Sodium bisulphite treatment deaminate cytosine to uracil, result-
ing in a mutation to thymine during reverse transcription, which 
then is revealed in the final sequencing dataset. Methylation of 
the cytosine at the fifth carbon position protects cytosine from 
this deamination. This strategy has been widely used in the study 
of DNA methylation to single base-pair resolutions37.
Given the harsh reaction conditions, sequencing bisulphite-
treated RNA was largely considered futile; however, adaptations 
to the protocol have enabled the use of bisulphite sequencing in 
a whole-transcriptome manner38. For these, a large quantity of 
RNA is required to be incubated at high temperatures in a buffer 
containing sodium bisulphite. RNA libraries then can be prepared 
by using a standard library preparation protocol for fragmented 
RNA. The identification of m5C sites then can be carried out 
by identifying events of cytosine conversion to thymidines in 
the treated sample against an untreated control or by compari-
son with a reference genomic dataset. Those sites that remain 
cytosines in the final data were protected by the methylation.
The limiting factor in bisulphite-RNA-sequencing is the ini-
tial large quantity of RNA required to compensate for the high 
losses caused by the bisulphite treatment; at the same time, 
neighbouring modifications or double-stranded regions may be 
resistant to bisulphite treatment, especially under the gentler 
treatment required to maintain the RNA integrity. At the same 
time, the most common modification to eukaryotic mRNA is 
m6A rather than m5C.
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Antibody-based sequencing and methods
The first whole-transcriptome maps of the internal m6A methyl-
ated nucleotide were published in 201239,40. Although these meth-
ods have been enhanced over the last 7 years, the principles have 
largely remained unchanged. Antibodies are available for most of 
the base modifications, and strategies to sequence them mostly 
follow the established “methylated RNA immunoprecipitation 
sequencing” (or “MeRIP-seq”)40.
The first two methods—named m6A-seq39 and MeRIP-seq40 
—were designed to detect N6-adenosine methylation in mRNA 
and long non-coding RNA but can be applied to any modifica-
tion with available antibodies; following isolation of poly(A) 
RNA, the RNA is fragmented to 100 base-pair lengths before 
being immunoprecipitated with an antibody to N6-methyl adeno-
sine (m6A). The precipitated fractions then can be sequenced 
with a standard RNA-sequencing approach. During the down-
stream bioinformatics, the fragments are aligned to the transcrip-
tome. Regions that are enriched after immunoprecipitation are 
assumed to contain a methylated nucleotide.
Although these early methods enabled the transcript-specific 
identification of methylated mRNAs, they suffer from low reso-
lution of about 100 to 200 nucleotides and require significant 
quantities of input RNA. Furthermore, if the antibody exhibits 
non-specific binding (for example, to a poly(A) stretch rather 
than a modified m6A site), false positives can be generated. To 
tackle some of these issues, recent methods have included 
ultraviolet crosslinking—with either an incorporated neighbour-
ing photoactivatable ribonucleotide (PA-m6A-seq41) or any nearby 
nucleotide (miCLIP42)—in order to induce detectible mutations 
or truncations during the downstream library preparation.
Antibodies can also be used in more traditional ways such as 
dot-blots43; this is an inexpensive method to assay for m6A 
modification but provides less information.
These strategies significantly increase the resolution gained 
from sequencing the precipitated fractions, although they still 
do not yield the quantitative stoichiometric information avail-
able through chromatography-based methods. Antibodies have 
been used to generate, for example, transcriptome-wide “MeRIP” 
maps of m6A39,40, m1A44 and m5C45,46 by using this general 
methodology, although issues surrounding the specificity of the 
antibodies used continue to be a point of contention47.
Reverse transcription stops
Owing to their reliance on antibodies or resistance to chemi-
cal deamination, many current methods for the analysis of RNA 
methylation are able to discern only the modifications to the 
base. To assay the modifications to the sugar-phosphate back-
bone of RNA or the “sugar edge” of the nucleotide, several 
methods that also allow sequence information to be maintained 
have emerged. These methods typically exploit changes to the 
biochemistry of the phosphate groups surrounding a change to 
the 2’-O-ribose methylated site.
Methylation at the 2’-O-ribose position confers resistance to 
alkaline hydrolysis at neighbouring nucleotides; alkali-hydrolysed 
RNA then can be ligated to an adaptor for reverse transcription 
and gaps revealed by RNA sequencing. This method has ena-
bled the transcriptome-wide sequencing of ribose methylations 
in rRNA48. An orthologous method performs reverse transcrip-
tion under a limiting concentration of dNTPs, causing some 
reverse transcriptases to stall and terminate cDNA synthesis 
at the site of 2’-O-ribose methylations. These truncations 
are then detectable during the downstream bioinformatics, 
as exploited by RTL-P49. However, this method requires that 
enough sequence information be maintained on the protected 
fragments, limiting its use at the ends of the RNA molecules.
Bioinformatics and processing
The data produced by the strategies described here are com-
plex, resulting in a growing need for robust bioinformatics 
approaches. Following alignment of the sequencing data to the 
genome or transcriptome, bioinformatics tools must interpret the 
peaks (antibody immunoprecipitation), troughs (reverse tran-
scriptase stops), or mutations (deaminations and non-canonical 
base pairing) in the sequencing data.
A typical bioinformatics workflow for mRNA methylation 
analysis begins with initial basecalling, adaptor trimming, and 
demultiplexing of both an untreated and an immunoprecipi-
tated sample for each replicate. Depending on the type of library 
preparation strategy used, collapsing polymerase chain reaction 
duplicates by identifying unique molecular barcodes included 
on the reverse transcription primer in order to increase the accu-
racy of the methylation quantification may be possible. Next, an 
alignment tool (for example, HISAT50 or STAR51) that is able 
to span exon–exon reads (or using a transcriptome index) is 
used to align the sequencing data to a known genome.
If a mutation is expected where methylation is deposited, the 
CLIP Tool Kit52 (CTK) CIMS algorithm can be used to call these 
sites, whilst a truncation site can be called with the CITS algo-
rithm. A number of software packages exist for analysis of CLIP 
data, such as MACS253, and these will work for RNA immu-
noprecipitated with antibodies to methylated nucleotides. The 
“peaks” generated in this way are areas of the genome that are 
enriched in the immunoprecipitated samples and so must contain 
the methylated nucleotide. If enough fragments are sequenced, 
locating the precise modified base is possible although this 
is dependent on the fragment size and sequencing depth of 
the employed sequencing technology.
Following the association of methylation with a gene’s tran-
script, further bioinformatics is likely to include motif analysis54 
for the identification of sequence contexts of the methylation and 
functional annotation such as Gene Ontology (GO) enrichment55 
in order to identify the enriched biological characteristics of 
genes. Other bioinformatics and experiments are likely to fol-
low in order to understand the biological consequences of 
the methylation; these are beyond the scope of the present 
work but consist largely of methods to assay the metabolism 
of the RNA56.
A note on “big data”
Where the methyl group is found at a location normally involved 
in base pairing (that is, the Watson–Crick edge of the nucle-
otide), reverse transcriptases are unable to pair the nucleotide 
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with its complement, resulting in a consistent “stop” or mutation 
during reverse transcription. These artefacts in the sequencing 
data may present an opportunity to detect possible methylations 
in publicly available datasets.
The increase in publicly available sequencing data has 
enabled the development of software such as HAMR57, which 
was able to discern tRNA modification sites from such public 
datasets. However, relying on reverse transcriptase dynamics can 
result in the loss of information about rare methylation events, 
methylation on rare transcripts, and stoichiometric information 
and thus is not so readily applicable to the analysis of mRNA.
The future of RNA methylation detection
Given the variety of methylated nucleotides found in RNA, it is 
likely to be some time before a single gold standard strategy 
exists which allows the preservation of all of the desired charac-
terisations, sequence, and stoichiometry information of a given 
modification. The most likely candidate appears to be nanopore 
sequencing technology, which uses changes in electrical charge 
to discern the nucleotides passing through a protein or graphene 
nanopore in substrate. Since these methods require no conver-
sion to DNA and analyse the nucleotide by how they affect 
the charge passing through the substrate, nanopore sequencing 
is also able to distinguish modified bases from their unmodi-
fied counterparts58. Whilst this technology is rapidly advancing, 
the current lack of read depth and requirement for high 
computing power appear to be the major limiting factors in 
the more widespread adoption of this technique for analysis 
of the diverse mammalian transcriptomes.
Given that methylated nucleotides can be used as biomark-
ers from a number of non-invasive tissues59, understanding their 
clinical roles is likely to be a major feature of future research. 
Therefore, the development of new technologies that can 
quickly identify the types of modifications found in disease is 
likely to be paramount to the application of epitranscriptomics 
both to medicine and in industry.
Summary
Methylation of nucleotides confers several unique properties 
to RNA during the life cycle of the molecule but also to their 
fundamental chemistry, which in recent years has been exploited 
in order to detect them. Owing to the huge variety of methylated 
nucleotides found in RNA, the epitranscriptomics revolution 
has lagged behind the epigenetics revolution by some 20 
years. However, study of these modifications has been rapidly 
evolving over the last decade because of the availability of 
new technology, and curiosity has been ignited by their new-
found associations with economically and medically important 
arenas of biochemistry.
In many ways, the technology remains the limiting factor. 
Currently, there is no single best way to detect and analyse the 
variety of structures associated with RNA methylation, often 
resulting in a need for a combinatorial approach to gain insights 
into their stoichiometry whilst maintaining sequence information 
(Table 2). It is the development of new technologies over the 
last decade that has allowed the novel insights into fundamental 
biological processes and disease, and it is the continued devel-
opment of these technologies that ultimately will lead towards 
an ability to rapidly detect the earliest signs of the changes 
to the cellular metabolism that may be indicative of disease. 
Better technological availability will also enable some of the 
growing controversies to be addressed, driven largely by the 
poor transparency of experimental protocols and poor understand-
ing of how best to analyse these novel sequencing datasets.
Deeper understanding of the epitranscriptome and its conse-
quences can only lead to a better ability to control gene expres-
sion in desirable ways. The epigenetics revolution is now 
leading to improved diagnostics and therapeutics for disease, 
and the fruits of the epitranscriptomics revolution are likely to 
be as exciting.
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